Stock DNA
Pharmaceuticals & Biotechnology
DKK 20,302 Million ()
69.00
NA
1.76%
-0.02
10.09%
3.36
Revenue and Profits:
Net Sales:
1,507 Million
(Quarterly Results - Jun 2025)
Net Profit:
123 Million
Total Returns (Price + Dividend) 
TimePeriod
Price Return
Dividend Return
Total Return
3 Months
-60.75%
0%
-60.75%
6 Months
-62.37%
0%
-62.37%
1 Year
0%
0%
0.0%
2 Years
0%
0%
0.0%
3 Years
0%
0%
0.0%
4 Years
0%
0%
0.0%
5 Years
0%
0%
0.0%
Ambu A/S for the last several years.
Risk Adjusted Returns v/s 
News
No Recent News for the Company
Announcements 
No announcement available
Corporate Actions 
No corporate action available
Quality key factors 
Factor
Value
Sales Growth (5y)
11.10%
EBIT Growth (5y)
12.35%
EBIT to Interest (avg)
9.56
Debt to EBITDA (avg)
1.09
Net Debt to Equity (avg)
-0.10
Sales to Capital Employed (avg)
0.83
Tax Ratio
15.53%
Dividend Payout Ratio
17.94%
Pledged Shares
0
Institutional Holding
0.00%
ROCE (avg)
6.79%
ROE (avg)
5.61%
Valuation key factors
Factor
Value
P/E Ratio
69
Industry P/E
Price to Book Value
4.19
EV to EBIT
53.53
EV to EBITDA
20.88
EV to Capital Employed
4.61
EV to Sales
4.04
PEG Ratio
NA
Dividend Yield
1.44%
ROCE (Latest)
8.61%
ROE (Latest)
6.08%
Technicals key factors
Indicator
Weekly
Monthly
MACD
Bearish
Bearish
RSI
No Signal
Bearish
Bollinger Bands
Bearish
Bearish
Moving Averages
Bearish (Daily)
KST
Bearish
Bearish
Dow Theory
Mildly Bullish
No Trend
OBV
Mildly Bullish
No Trend
Shareholding Snapshot : Jun 2023
Shareholding Compare (%holding) 
Majority shareholders
Strategic Entities
Domestic Funds
Held in 0 Schemes (0%)
Foreign Institutions
Held by 0 Foreign Institutions (0%)
Strategic Entities with highest holding
Highest Public shareholder
Quarterly Results Snapshot (Consolidated) - Jun'25 - YoY
Jun'25
Jun'24
Change(%)
Net Sales
1,507.00
1,383.00
8.97%
Operating Profit (PBDIT) excl Other Income
263.00
267.00
-1.50%
Interest
13.00
7.00
85.71%
Exceptional Items
0.00
0.00
Consolidate Net Profit
123.00
134.00
-8.21%
Operating Profit Margin (Excl OI)
112.80%
128.70%
-1.59%
USD in Million.
Net Sales
YoY Growth in quarter ended Jun 2025 is 8.97% vs 15.73% in Jun 2024
Consolidated Net Profit
YoY Growth in quarter ended Jun 2025 is -8.21% vs 162.75% in Jun 2024
Annual Results Snapshot (Consolidated) - Sep'24
Sep'24
Sep'23
Change(%)
Net Sales
5,391.00
4,775.00
12.90%
Operating Profit (PBDIT) excl Other Income
1,006.00
632.00
59.18%
Interest
27.00
61.00
-55.74%
Exceptional Items
-331.00
-7.00
-4,628.57%
Consolidate Net Profit
235.00
168.00
39.88%
Operating Profit Margin (Excl OI)
119.10%
63.20%
5.59%
USD in Million.
Net Sales
YoY Growth in year ended Sep 2024 is 12.90% vs 7.45% in Sep 2023
Consolidated Net Profit
YoY Growth in year ended Sep 2024 is 39.88% vs 80.65% in Sep 2023
About Ambu A/S 
Ambu A/S
Pharmaceuticals & Biotechnology
Ambu A/S is a Denmark-based company engaged in the development, manufacture and marketing of diagnostic and life-supporting devices for hospitals and rescue services. The Company’s operations are structured into three business areas: Anaesthesia, Patient Monitoring & Diagnostics and Emergency Care. The Anaesthesia business area offers a range of products from resuscitators, face masks and laryngeal masks to the single use flexible intubation scope. The Patient Monitoring & Diagnostics business area comprises single use electrodes for cardiological and neurological examinations. The target groups for these products are hospitals, clinics, ambulance services and sleep labs. The Emergency Care business area offers ventilation bags, neck collars and manikins for first-aid training. The Company markets its products worldwide. The Company operates King Systems Inc, First Water Heathcote Ltd and Invendo Medical GmbH as subsidiaries.
Company Coordinates 
Company Details
Baltorpbakken 13 , BALLERUP None : 2750
Registrar Details






